How Does Datroway Work for Breast Cancer? Datroway is a type of medicine known as an antibody drug conjugate (ADC). The ADC is designed to deliver medicine directly to the cancer cells and is made ...

The company states: “Datroway, or Dato-DXd, has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor HR-positive, HER2-negative breast ...

The drug, called Datroway (datopotamab deruxtecan), is approved for patients who have already received endocrine-based therapy and chemotherapy. Datroway is part of a new class of medications ...

Among 35 patients who received Datroway at a lower 4 mg/kg dose, investigators recorded a 43% ORR for the combination. The two patient groups had similar follow-up times at about 13 months ...

Japanese drugmaker Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in the company’s home country for the treatment of adults with hormone receptor (HR) positive, HER2 negative, ...

The US regulator has cleared TROP2-directed ADC datopotamab deruxtecan (Dato-DXd) under the Datroway trade name as a treatment for previously treated HR+/HER2- breast cancer, a few weeks after its ...

Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been launched in Japan for the treatment of adult patients with hormone receptor (HR) positive, HER2 negative (IHC 0, IHC 1+ or IHC 2+/ISH-) ...

It is the first global approval for the drug – which has been cleared under the Datroway brand name – with Japan's Ministry of Health, Labour and Welfare (MHLW) backing its use for patients ...

AstraZeneca’s Datroway, an antibody drug conjugate (ADC), is now FDA approved for advanced cases of breast cancer that is HR positive and HER2 negative. Datroway targets TROP2, the same cancer ...

6. AstraZeneca offers early look at Datroway-Tagrisso combo in EGFR lung cancer as phase 3 trial rolls on AstraZeneca found that a combination of its Daiichi Sankyo-partnered Datroway and Tagrisso ...

New study results presented at the European Lung Cancer Congress (ELCC) 2025, 26 to 29 March, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel ...